Fluconazol plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study

Abstract

In a retrospective study the incidence of infections, number of afebrile days, duration of antimicrobial chemotherapy, and cost of antibacterials and antimycotics were compared in two groups of patients. One was a group of 57 patients who received no prophylaxis during induction remission therapy of acute leukemia treated in 1989-1990, the second was a group of 22 patients treated in 1991 where prophylaxis with fluconazol and ofloxacin was administered. For ethical reasons pertaining since 1991, when prophylaxis became mandatory, the study was not randomized. A decrease in the number of febrile days, the cost of antimicrobials and the duration of treatment with antibiotics and antimycotics was observed in the group receiving fluconazol and ofloxacin.

Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies

“…Additionally, three other studies were excluded as they did not include a full costbenefit or cost-effectiveness analysis. [25][26][27] Poirier et al [25] estimated the costs of different prophylactic itraconazole dosing regimens only including drug acquisition costs, while Sajben et al [26] compared only costs of antibacterial treatment in patients who received prophylaxis (i.e. fluconazole plus ofloxacin) with those who did not.…”